EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development



RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development



Clinical Cancer Research 14(12): 3948-3955



To recapitulate the generation of cancer stem cells in the context of an intact animal using a retroviral vector capable of in vivo delivery of oncogenes to primitive endothelial and hematopoietic stem cells. Targeting of these progenitors was achieved using transgenic mice in which the avian TVA retroviral receptor was placed under the control of the stem cell leukemia (scl/tal-1) gene promoter and SCL +19 enhancer. Injection of an avian retrovirus encoding polyoma middle T (PyMT), an oncogene that transforms endothelial cells, caused rapid lethality in all SCL-TVA mice but not in control TVA(-) littermates. The infected animals exhibited hemorrhagic foci in several organs. Histopathologic analysis confirmed the presence of hemangiomas and the endothelial origin of the PyMT-transformed cells. Surprisingly, the transformed endothelial cells contained readily detectable numbers of TVA(+) cells. By contrast, normal blood vessels had very few of these cells. The presence of TVA(+) cells in the lesions suggests that the cells originally infected by PyMT retained stem cell characteristics. Further analysis showed that the tumor cells exhibited activation of the phosphatidylinositol 3-kinase/Akt and S6/mammalian target of rapamycin pathways, suggesting a mechanism used by PyMT to transform endothelial progenitors in vivo. We conclude that this experimental system can specifically deliver oncogenes to vascular endothelial progenitors in vivo and cause a fatal neoplastic disease. This animal model should allow the generation of endothelial cancer stem cells in the natural environment of an immunocompetent animal, thereby enabling the recapitulation of genetic alterations that are responsible for the initiation and progression of human malignancies of endothelial origin.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333733

Download citation: RISBibTeXText

PMID: 18559617

DOI: 10.1158/1078-0432.CCR-07-5152



Related references

Disruption of vascular development and formation of hemangiomas by endothelial cells expressing polyoma middle t oncogene. Journal of Cellular Biochemistry Supplement (13 PART E): 195, 1989

RCAS-TVA in the mammary gland: an in vivo oncogene screen and a high fidelity model for breast transformation?. Cell Cycle 6(7): 823-826, 2007

Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. Biochemistry & Cell Biology 70(7): 579-592, 1992

Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 52(1): 121-131, 1988

Tissue specificity of oncogene action: endothelial cell tumours in polyoma middle T transgenic mice. Iarc Scientific Publications: 255-266, 1989

Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene. Cell 51(4): 529-537, 1987

Embryonic lethalities and endothelial tumors in embryonal stem cell chimeras expressing polyoma middle t oncogene. Journal of Cellular Biochemistry Supplement (12 PART A): 176, 1988

Hemangioma development in transgenic mice carrying polyoma middle t antigen. Journal of Cellular Biochemistry Supplement (11 PART C): 136, 1987

A preliminary study of murine hemangioma model by delivery of recombinant adeno-associated virus mediated human vascular endothelial growth factor-121 gene. Zhonghua Kou Qiang Yi Xue Za Zhi 44(3): 162-164, 2011

Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine 10(8): 1711-1718, 2015

Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene. Cancer Research 53(16): 3812-3816, 1993

MRI molecular imaging using GLUT1 antibody-Fe3O4 nanoparticles in the hemangioma animal model for differentiating infantile hemangioma from vascular malformation. Nanomedicine 11(1): 127-135, 2015

Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. International Journal of Nanomedicine 6(): 1661-1673, 2012